

March 24, 2016



Actinium to Present at Sidoti Spring 2016 Emerging Growth Convention

Company Presentation Scheduled for Thursday, March 31, 2016 at 3:00 PM ET

NEW YORK, NY -- (Marketwired) -- 03/24/16 --

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or the "Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that members of its executive management team will attend the Sidoti Spring 2016 Emerging Growth Convention being held at the New York Marriott Marquis, New York on March 31, 2016. Sandesh Seth, Actinium's Executive Chairman, will present an overview of the Company on Thursday, March 31, 2016 at 3:00 PM ET. A webcast of the presentation will be available through Actinium's investor relations page <http://ir.actiniumpharma.com/ir-calendar>.

Event: Sidoti Spring 2016 Emerging Growth Convention
Location: New York Marriott Marquis, NYC
Date: March 31, 2016

Management will be available for 1-on-1 meetings with conference attendees. To schedule a meeting please contact Steve O'Loughlin, Vice President, Finance and Corporate Development at soloughlin@actiniumpharma.com.

About the Sidoti Emerging Growth Convention

The Sidoti Spring 2016 Emerging Growth Convention will focus on companies with market capitalizations of \$500 million and less, connecting their executive management teams with Wall Street's top small- and micro-cap institutional and high-net-worth investors, research and investment banking professionals and other key stakeholders in the micro-cap investment community. Last year's debut convention featured 55 public companies and approximately 400 attendees, including nearly 275 registered institutional investors. For more information, please refer to www.sidoti.com.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with

monoclonal antibodies. The Company's lead radiopharmaceutical product candidate lomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of lomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Steve O'Loughlin

Vice President, Finance and Corporate Development

Actinium Pharmaceuticals, Inc.

soloughlin@actiniumpharma.com

Source: Actinium Pharmaceuticals